The community for GLP-1 answers
and everyday remedies.
Ask real people about semaglutide side effects, tirzepatide dosing, natural alternatives like berberine, and the everyday remedies you actually search for. Every dictionary entry is sourced from openFDA, RxNorm, MedlinePlus and ClinicalTrials.gov.
remedy.med is a community discussion platform, not medical advice. Content is user-generated and not verified by medical professionals. Consult a licensed healthcare provider before trying any remedy, especially if pregnant, on medication, or managing a chronic condition.
Every major GLP-1, cross-referenced
Indications, warnings, and natural adjuncts — sourced, not sponsored.
What's new: FDA labels, recalls & clinical trials
Live pulled from openFDA and ClinicalTrials.gov — refreshed every 30 minutes.
- Trial· ClinicalTrials.gov2026-09-01
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Trial· ClinicalTrials.gov2026-09-01
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
- Trial· ClinicalTrials.gov2026-09-01
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to
- Trial· ClinicalTrials.gov2026-09-01
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
Background: Artificial sweeteners like sucralose are found in many foods and drinks. Sucralose might affect hormones and cause health changes. Objective: To see if sucralose changes how medicines are absorbed and processed, how hormones
- Trial· ClinicalTrials.gov2026-09-01
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
- Trial· ClinicalTrials.gov2026-08-31
Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis
This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance
- FDA label· openFDA Drug Label2026-07-30
Updated FDA label: Ozempic (SEMAGLUTIDE)
1 INDICATIONS AND USAGE OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infa
- FDA label· openFDA Drug Label2026-07-29
Updated FDA label: MOUNJARO (TIRZEPATIDE)
1 INDICATIONS AND USAGE MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptid
- FDA label· openFDA Drug Label2026-07-27
Updated FDA label: Liraglutide (LIRAGLUTIDE)
1 INDICATIONS AND USAGE Liraglutide Injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use : Liraglutide Injection contai
- FDA label· openFDA Drug Label2026-06-16
Updated FDA label: Trulicity (DULAGLUTIDE)
1 INDICATIONS AND USAGE TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events
- Recall· openFDA Enforcement2022-04-05
Trulicity (dulaglutide) injection, 0.75 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only,
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions — Class Class II · Cardinal Health Inc.
- Recall· openFDA Enforcement2022-04-05
Trulicity (dulaglutide) injection, 1.5 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only,
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather. — Class Class II · Cardinal Health Inc.
Browse everyday remedies
Herbs, supplements, OTC drugs, and home remedies for the questions you actually search.